The use of combination cytotoxic chemotherapy as palliation for patients with advanced breast cancer became established in the late 1960s (Cooper et al., 1969) . Few trials show a survival advantage for a particular regimen and only recently has an overall improvement in survival been associated with treatments giving higher response rates (1976) . Since then, QoL measurement in cancer patients has been advocated widely (Maguire & Selby, 1989) . However, in 1986, Macaulay and Smith reported that in a review of over 230 advanced breast cancer trials, in only two had overall QoL been measured. They added that assessment of the value of particular treatments should not rest upon response rate alone (Macaulay & Smith, 1986) . So (Slevin et al., 1988) . One problem may have been the QoL instruments on offer. Well-validated instruments did not include items about vomiting, nausea or hair loss and none was specific to breast cancer or chemotherapy. Moreover, QoL measurement is labourintensive. We therefore addressed these problems.
In QoL measurement, a gold standard does not exist, and according to Bergner, is not desirable (Bergner, 1984 (Ebbs et al., 1989) . This development process resulted in the 'Qualitator' and has been described previously (Fraser et al., 1990 . A relationship between poor QoL and poor survival was reported by Morris and Sherwood in a study of terminally ill patients (Morris & Sherwood, 1987 (Hunt et al., 1985) and the Linear Analogue Self-Assessment (LASA) (Priestman & Baum, 1976) . The NHP was chosen as a well validated general measure of QoL and the LASA because it is an instrument which has been used and validated extensively in breast cancer trials (Boyd et al., 1988) . QoL measurement was continued for 6 months or until treatment failure.
In the second study, at Guy's Hospital, 39 patients were randomised to receive doxorubicin 25 mg m-2 weekly or 75 mg m-2 three-weekly to examine the influence of treatment schedule on response, survival and quality of life. Thirty one patients completed the diary in its preliminary format between 1986 and 1987 , at the commencement of 12 weeks of therapy (Richards et al., 1992) Figure 1) . From 23 items the patient chooses one she considers the most important from each of four domains: (1) symptoms of disease and side effects of treatment, (2) psychological aspects, (3) personal relationships and (4) physical performance. In addition a weighting variable is chosen from any domain. Daily thereafter, a score from 1-4 is given to the five chosen items, corresponding to the severity with which each item is perceived: 'Not at all', 'A Little', 'Somewhat', 'Very Much'. The opportunity to change items occurs every three weeks, when a new card is exchanged for the old one. This period was chosen to suit the regimens used in the initial study (Ebb et al., 1988) and was kept for subsequent studies. Each patient's aggregated daily score is added to obtain a weekly total in the range 35-140. In both studies, patient groups (and other QoL measures in the King's study) were compared using a mean diary score taken from the completed weeks during each successive four week period. This allowed inclusion of all the available data, but allowed for any missing weeks. Isolated missing days were given the mean score for the other days that week.
In (Kaplan & Meier, 1958) and the log-rank test (Peto et al., 1977 (2) The Guy's study The missing weeks were 13 (11%) of 123 in the weekly treatment arm and 46 (21%) of 220 in the 3-weekly treatment arm (X2 = 5.92, P <0.02). Missing weeks were incurred most often as a result of delayed treatment due to haematological toxicity, and omission of the diary during the interim recovery period. There were 15 isolated missing days. Figure   2 , standardised to a common scale of 0-10.
QoL and survival
To assess the relationship between early Qualitator scores and subsequest survival, the 60 patients from both studies were divided into high scoring and low scoring groups of nearly equal size using a threshold score of over 65. Survival was significantly better for patients with low scores in both the first week (median survival 57 weeks, 33 weeks; x2 = 5.77, ldf, P<0.02) and the first 4 weeks (median survival 57 weeks, 30 weeks; x2 = 14.48, ldf, P <0.001). The survival curves are illustrated in Figures 3a and b .
In the King's study, an above median Qualitator score at the start of treatment was of greater prognostic significance than any other factor (see Table I ).
QoL during treatment according to response The intial difference between the diary scores of responders and non-responders persisted for 3 months in the King's study (P = 0.022, P = 0.033, P = 0.010) and 4 months in the Guy's study (P = 0.021, P = 0.0498, P = 0.028, P = 0.043). The corresponding differences in global scores for the NHP and LASA in the King's study were not significant after 1 month.
Comparing patients' first week's Qualitator score with the corresponding aggregated score for 1, 2 and 3 months, there were signficant improvements for responders in the King's study at two months (median 8.55, P <0.05) and 3 months (median 12.5, P <0.01). There was no differences in the scores of non-responders. In the same patients, a similar pattern was observed in the NHP responders at 3 months (median 67.8, P <0.06) though less so in the LASA (median 1.75, P < 0.8). The same trend of improvements in QoL score were not significant in Guy's responders. In order to illustrate the weekly trend in QoL scores amongst patients, Figure 4 shows the mean diary scores in each group (although non-parametric methods were used for statistical analysis).
QoL during treatment according to therapy Comparing the change in Qualitator scores, between the first week and the subsequent aggregated score for 1, 2 and 3 months, an improvement was recorded in the King's study for both Epirubicin (median 7.2, P < 0.02) and CMF (median 8.93, P<0.02) patients remaining at 3 months. This pattern was seen in the NHP score at 3 months for the same patients on CMF (Median 67.75, P<0.02). In the Guy's study, patients on the 3 weekly regimen had improved Qualitator scores at three months (median 9.4, P<0.05). In the separate items, in the King's study, the only significant change was that at 3 months the scores for pain had improved for responders (medians 15 to 8.25, P<0.02) but not for non-responders (15.25 to 16). A similar, though nonsignificant trend was observed in the Guy's study.
Discussion
There is no common currency of QoL measurement. In advanced breast cancer, QoL comprises many facets and as in other cancers, symptoms change in importance between patients and over time (Clement Jones, 1985) ; chemotherapy adds to this complexity. The recently developed Rotterdam Symptom Checklist (RSC) is a multidimensional instrument specifically designed for advanced cancer patients on chemotherapy which measures many facets but at intermittent timepoints (de Haes et al., 1990) . The development of the Qualitator represents a different response to the same perceived problem, rather than at attempt to 'reinvent the wheel' (Aaronson, 1988) .
The frequency of diary completion allows few items. Geddes et al. used a diary comprising eight obligatory items to measure QoL in lung cancer patients receiving chemotherapy (Geddes et al., 1990) . Fallowfield pointed out that most QoL questionnaires have fixed components that might not be relevant to an individual (Fallowfield, 1990) . The Qualitator only measures five items on any 3 week cycle. However, permitting the patient to define areas of her life contributing most to its overall quality was the most novel and important departure from more traditional instruments. Lumping symptoms altogether in a global measurement is regarded by some as unscientific, askin to 'trying to compare apples and oranges'. This, however, was the intention: the sum of the parts was of overall interest. The number of changes of item made by patients in both studies supports this view.
In spite of small numbers in both the King's and Guy's studies, the Qualitator can predict patients likely to respond, supporting the findings of Baum et al. (1980) and Ebbs et al. (1988) . Moreover, patients with high initial scores had poorer survival, supporting the findings of Morris and Sherwood (1987) and Addington-Hall et al. (1990) .
Compliance for diary completion overall was good in both the King's study and Guy's study, comparing favourably with Geddes et al. who obtained 85%. In both studies, more QUALITY OF LIFE MEASUREMENT FOR BREAST CANCER 345 (Aaronson, 1988 (Ware, 1987 Of the three instruments used in the Kings' study, the Qualitator was easiest to administer as it was completed by the patient at home. Data processing was time consuming for all three, requiring entry on a computer spreadsheet, but arrival at a global score quickest for the qualitator.
The Qualitator is not presented as the long-awaited goldstandard and modification may be desirable with experience. However, where simplicity of use and a single global QoL score are desired, the Qualitator illustrates that collecting the patient's chosen symptoms together and measuring the score over time is feasible. When so few studies at present involve
